When did BARINTHUS BIOTHERAPEUTICS PL (BRNS) report earnings last quarter?
BARINTHUS BIOTHERAPEUTICS PL (BRNS) last reported earnings on 3/13/2026.
BARINTHUS BIOTHERAPEUTICS PL (BRNS) Earnings History & Surprises
NASDAQ:BRNS • US91864C1071
Current stock price
0.63 USD
+0 (+0.77%)
Last:
BRNS Earnings overview
Past quarterly earnings results for BARINTHUS BIOTHERAPEUTICS PL (BRNS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.29
- Revenue Estimate
Last Reported
Most Recent- Release Date
- Mar 13, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.27
- EPS Surprise
- 23.27%
- Revenue Surprise
- %
Beat Rate
Last 8 Quarters 25%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.27 | -0.35 | 23.27% | 47.06% | - | - | ||
| Q3 2025 | -0.24 | -0.40 | 40.43% | -14.29% | - | -100.00% | ||
| Q2 2025 | -0.52 | -0.34 | -54.49% | -20.93% | - | - | ||
| Q1 2025 | -0.49 | -0.37 | -33.44% | -22.50% | - | - | ||
| Q4 2024 | -0.51 | -0.42 | -20.97% | -13.33% | - | - | ||
| Q3 2024 | -0.21 | -0.45 | 53.56% | 43.24% | 14.969M | - | - | |
| Q2 2024 | -0.43 | -0.42 | -1.99% | 30.65% | - | -100.00% | ||
| Q1 2024 | -0.40 | -0.55 | 27.91% | 16.67% | - | -100.00% | ||
| Q4 2023 | -0.45 | -0.51 | 11.66% | 20.63% | 131.325K | -100.00% | -100.00% | |
| Q3 2023 | -0.37 | -0.54 | 31.56% | -268.18% | 255K | -100.00% | -100.00% | |
| Q2 2023 | -0.62 | -0.56 | -11.12% | -251.22% | 334K | 612K | -45.42% | -98.04% |
| Q1 2023 | -0.48 | -0.51 | 6.51% | -785.71% | 468K | 1.53M | -69.41% | -96.88% |
| Q4 2022 | -0.57 | -0.43 | -30.80% | -49.21% | 6.457M | 3.378M | 91.15% | 2,309.33% |
| Q3 2022 | 0.22 | -0.34 | 165.36% | 269.23% | 6.165M | 7.978M | -22.72% | 32,347.37% |
| Q2 2022 | 0.41 | -0.33 | 224.35% | 164.06% | 17.063M | 3.637M | 369.15% | 48,651.43% |
| Q1 2022 | 0.07 | -0.32 | 122.14% | 107.37% | 15.018M | 3.639M | 312.70% | 6,885.12% |
| Q4 2021 | -0.38 | -0.31 | -21.15% | - | 268K | 414.803K | -35.39% | -24.14% |
| Q3 2021 | -0.13 | -0.46 | 71.83% | - | 19K | 1.122M | -98.31% | -99.42% |
| Q2 2021 | -0.64 | -0.75 | 15.21% | - | 35K | 102K | -65.69% | - |
| Q1 2021 | -0.95 | -2.15 | 55.86% | - | 215K | 102K | 110.78% | - |
| Q4 2020 | - | - | 353.3K | - | - | |||
| Q3 2020 | - | - | 3.251M | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-6.06%
Max EPS beat (4)
40.43%
Min EPS beat (4)
-54.49%
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
In the last 4 quarters, BRNS has beaten EPS estimates in 2 out of 4 releases
In the last 4 quarters, BRNS reported -6.1% below the EPS estimates on average.
Related analysis
BARINTHUS BIOTHERAPEUTICS PL / BRNS Earnings FAQ
Did BRNS stock beat earnings estimates in the most recent quarter?
BARINTHUS BIOTHERAPEUTICS PL (BRNS) beat EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often BARINTHUS BIOTHERAPEUTICS PL beats earnings estimates?
In the last 4 quarters, BARINTHUS BIOTHERAPEUTICS PL (BRNS) has beaten EPS estimates in 2 out of 4 releases.